BDBM572201 (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-10,11,12,13,14,15-hexahydro-2H-pyrazolo[4′,3′:4,5]azacycloundecino[3,2,1-hi]indole-8-carboxylic Acid::US11447504, Example 54::US11478451, Example 071

SMILES CCc1c-2c(CCCCCCn3c(C(O)=O)c(CCCOc4cccc5cc(F)ccc45)c4ccc(Cl)c-2c34)nn1C

InChI Key InChIKey=OHARMQWZWCLEAS-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 572201   

LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 21nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 25nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent